Evidence map›Paper›PMID 40895532›Full record

ArticleFrontiers in immunology2025

Thura Akrem Omran, Jose Luis Subirats Camacho, Thulasika Senthakumaran, Gro Gundersen, Annette Knapskog Alte, Ulla Randen, Hege Smith Tunsjø, Per Christian Sæther, Vahid Bemanian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Cancers · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thura Akrem OmranDepartment of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway.
Jose Luis Subirats CamachoDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.
Thulasika SenthakumaranDepartment of Microbiology and Infection Control, Akershus University Hospital, Lørenskog, Norway.
Gro GundersenDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.
Annette Knapskog AlteDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.
Ulla RandenDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.
Hege Smith TunsjøDepartment of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway.
Per Christian SætherDepartment of Immunology and Transfusion Medicine, Akershus University Hospital, Lørenskog, Norway.
Vahid BemanianDepartment of Pathology, Akershus University Hospital, Lørenskog, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The gut microbiome may significantly influence the development of colorectal cancer (CRC), with Methods: Tumor samples from 25 CRC patients were divided by Results: Analysis of differential immune gene expression, combined with correlation analyses, identified 25 genes, including C-X-C motif chemokine ligand 8 (CXCL8), interleukin-6 (IL6), indoleamine 2,3-dioxygenase 1 (IDO1), and secreted phosphoprotein 1 (SPP1), that exhibited significant associations with Conclusions: High

Indexed as

Colorectal NeoplasmsFusobacteriumFusobacterium InfectionsAgedCohort StudiesFemaleGastrointestinal MicrobiomeGene Expression Regulation, NeoplasticHumansMacrophagesMaleMicrosatellite InstabilityMiddle AgedNorwayPilot ProjectsTumor Microenvironmentcolorectal cancer (CRC)fap2Fusobacteriumgene expressionimmune genesNorway

Identifiers

PMID40895532
PMCPMC12391062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.